Abstract
Better knowledge of the bioavailability and metabolism of isoflavones in prostate tissue is needed to further investigate their mechanisms of action in the context of prostate cancer prevention. A total of 12 men with benign prostatic hyperplasia received soy extract supplementation (3 Evestrel (R) capsules, providing a total of 112.5 mg isoflavones aglycone eq/day) for 3 days before prostate surgery. Blood and prostate tissues were sampled and metabolites were identified using electrospray ionization liquid chromatography tandem mass spectrometry (LC-ESI-MS/MS) and chemically synthesized standards of glucuronidated isoflavones. The main metabolites were the same in prostate tissue and in plasma, namely, 2 monoglucuronides of daidzein and 2 monoglucuronides; of genistein. Concentrations of total isoflavones; measured in prostate reached 1.05 +/- 0.62 nmol/g tissue (range 0.30-2.23) at the time of sampling, 12 h after the last isoflavone supplementation. At that time point, prostate concentrations were lower than plasma concentrations in all volunteers: 0.47 nmoL/g vs. 0.66 mu M for daidzein and 0.58 Nmol/g vs. 0.78 mu M for genistein. Isoflavone mechanisms of action should thus be investigated in in vitro cell studies using physiological conditions, intracellular concentrations below 5 nmol/g and no intracellular deconjugation of the monoglucuronide metabolites.
Original language | English |
---|---|
Pages (from-to) | 461-468 |
Number of pages | 8 |
Journal | Nutrition and Cancer |
Volume | 60 |
DOIs | |
Publication status | Published - Jul 2008 |
Keywords
- PURIFIED SOY ISOFLAVONES
- PHYTO-ESTROGENS
- CANCER RISK
- IN-VITRO
- MEN
- GENISTEIN
- PLASMA
- METABOLITES
- IMMIGRANTS
- DAIDZEIN